Claudio has broad international experience in medical affairs with a focus on serious viral infectious diseases, including COVID-19, hepatitis and HIV.
Prior to joining Atea, Claudio served in roles of increasing responsibility at Gilead Sciences, most recently as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19. Prior roles at Gilead Sciences included Medical Affairs leadership of the Asia Pacific region, including Japan and China; and for HCV in Europe, the Middle East and Australia. Earlier in his career, Claudio was a Global Program Medical Director for Hepatitis B and C development at Novartis Pharma AG and his first industry role was as Medical Advisor in HIV at GlaxoSmithKline (UK). Claudio’s medical career was as honorary infectious diseases physician in the United Kingdom and medical officer in Australia.
Claudio received his medical degree (MB, BS) from Sydney University and BSc (Hons) / PhD from Melbourne University. He has authored more than three dozen peer-reviewed publications.Back to Full Team